Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
Keros Therapeutics Inc (NASDAQ: KROS) had a dream debut, with the company pricing the shares at the high-end of the estimated range and the shares closing the debut session about 26% higher than the IPO price.
This upcoming week is likely to continue to see more pre-announcements and disclosures regarding how the COVID-19 pandemic is impacting operations, cash position, financials and clinical trials.
Needham Virtual Healthcare Conference: April 14-15
The FDA is set to rule Saturday on Urogen Pharma Ltd’s (NASDAQ: URGN) NDA for UGN-101 (mitomycin gel), which is being evaluated for the treatment of low-grade, upper tract urothelial cancer.
Vir Biotechnology Inc (NASDAQ: VIR) on Wednesday will present at a Key Opinion leader call, an update on its Phase 1/2 hepatitis B virus clinical trial with small interfering ribonucleic acid VIR-2218. Vir had licensed the investigational asset from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).
See Also: Novavax Identifies COVID-19 Vaccine Candidate, Human Testing To Begin In Mid-May
Ascendis Pharma A / S (NASDAQ: ASND): top-line data from PaTH Forward Phase 2 study of TransCon hGH in treating hypoparathryroidism
Gilead Sciences, Inc. (NASDAQ: GILD) could release results from the Phase 3 China studies of remdesivir for the treatment of COVID-19 (sell-side estimate a mid-April release)
Early Q2 Schedule
Axsome Therapeutics Inc (NASDAQ: AXSM): top-line data from the Phase 2/3 study dubbed ADVANCE-1 that is evaluating AXS-05 for treating agitation in patients with Alzheimer’s disease
SCYNEXIS Inc (NASDAQ: SCYX): top-line data from Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis
Ovid Therapeutics Inc (NASDAQ: OVID): data from the signal-finding Phase 2 ROCKET trial in Fragile X syndrome along with SKYROCKET, its non-interventional trial in Fragile X syndrome.
Iterum Therapeutics PLC (NASDAQ: ITRM): top-line results from the Phase 3 study of sulopenem in complicated urinary tract infection and uncomplicated urinary tract infection
- Amarin Corporation plc (NASDAQ: AMRN) (after the close)
- Johnson & Johnson (NYSE: JNJ) (before the market open)
- Abbott Laboratories (NYSE: ABT) (before the market open)
- Intuitive Surgical, Inc. (NASDAQ: ISRG) (after the close)
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.